Letters to the Editor

Sofosbuvir May be a Potential Anti-SARS-CoV-2 RdRp Drug

1Mohamed Nabil Ibrahim and 2Abdo Abdellah Elfiky

1Department of Clinical Laboratory Sciences, Jouf University, Saudi Arabia
2Department of Biophysics, Cairo University, Egypt

Abstract: The Coronavirus Diseases 2019 (COVID-19) seriously affecting human health all over the world. More than 107 M people are reported positive for SARS-CoV-2, the virus causing COVID-19 pneumonia, from which +2.3 M died. Nucleotide Inhibitors (NI) have promising results in terms of its efficacy against different viral polymerases, including the Hepatitis C Virus (HCV) Non-Structural Protein 5 B (NS5B) RNA dependent RNA polymerase (RdRp) 1. Thus, the non-structural protein 12 (nsp12) RdRp of the human coronavirus represents an attractive target to develop a possible therapeutic agent. Sofosbuvir proved itself as a potential anti-SARS-CoV-2 RdRp and could inhibit viral replication and infection propagation.

Keywords: Sofosbuvir-COVID-19-RNA Polymerase-Therapy

Dear Editor

Coronavirus Diseases 2019 (COVID-19) seriously affecting human health all over the world. More than 149 M people are reported positive for SARS-CoV-2, the virus causing COVID-19 pneumonia, from which +3.15 M died. Nucleotide Inhibitors (NI) have promising results in terms of their efficacy against different viral polymerases, including the Hepatitis C Virus (HCV) Non-Structural Protein 5 B (NS5B) RNA dependent RNA polymerase (RdRp) (Gane et al., 2013). Thus, the non-structural protein 12 (nsp12) RdRp of the human coronavirus represents an attractive target to develop a possible therapeutic agent.

The Ebola virus NI, Remdesivir, was authorized for emergency use by the Food and Drugs Administration (FDA) against COVID-19 in May 2020. Various studies reported the in silico effectiveness of other nucleotide inhibitors currently in the market against SARS-CoV-2 (Elfiky, 2020a). The study utilized a structure of SARS-CoV-2 RdRp for small molecule screening. Also, protein dynamics were simulated for 100 ns. Sofosbuvir is currently used for HCV treatment since the FDA approved it in 2013 (Gane et al., 2013). The safety profile of Sofosbuvir was tested over millions of people worldwide and different companies are manufacturing it at affordable prices in low-income countries like India and Egypt (Omar et al., 2018; Elsharkawy et al., 2017; Shah et al., 2017). Sofosbuvir is able to bind to RdRp of SARS-CoV-2 with comparable binding energies compared to Remdesivir (Fig. 1) (Elfiky, 2020b; Jácome et al., 2020; Elfiky et al., 2021).

The dynamics were simulated using the NAMD software utilizing the CHARMM36 force field (Huang and MacKerell, 2013; Phillips et al., 2005). A water box (TIP3P model) is added to the system with added NaCl salt concentration adjusted to be in the physiological value (154 mM) (Mark and Nilsson, 2001). After dynamics, Maestro is utilized to cluster the trajectories to be tested using the docking protocol (Schrödinger, 2017-1). AutoDock Vina is used in the docking study, while AutoDock tools and PyMOL are used to prepare the docking files and to analyze the data (Rauf et al., 2015; Trott and Olson, 2010). The docking grid was adjusted to cover the active site aspartates (D760 and D761) using the flexible ligand and flexible active site protocol.

As reflected in Fig. 1, the Sofosbuvir is successfully fitted inside the nucleotide channel by forming contacts with the channel-lining residues (blue sticks in the lower enlarged panel of Fig. 1). Six H-bonds (with S549, R555(2), R624(2) and N691), four hydrophobic contact (with Y455, K551, R553 and K621) and two salt bridges (with R555 and R624) are established.

The binding affinity of Sofosbuvir (-7.4±0.3 kcal/mol) is very close to that for Remdesivir (-7.3±0.1 kcal/mol) against SARS-CoV-2 RdRp. This affinity is persistent during 25 ns MDS run on the formed complex. In previous studies on a model for SARS-CoV-2 RdRp built before the first structure was released, Sofosbuvir shows similar results regarding the binding affinity and the binding mode (Elfiky, 2020a-c; Jácome et al., 2020). Sofosbuvir proved its safety and anti-HCV activity during the last eight years and may be a potential SARS-CoV-2 inhibitor.

© 2021 Mohamed Nabil Ibrahim and Abdo Abdellah Elfiky. This open access article is distributed under a Creative Commons Attribution (CC-BY) 4.0 license.
Fig. 1: Sofosbuvir at SARS-COV-2 RdRp active site pocket. The docking pose of sofosbuvir (orange sticks) in the active site of SARS-COV-2 RdRp (conformation at 28.1 ns) (surface) depicted by PyMOL software. The interactions are shown in blue, dashed gray and dashed-yellow lines for H-bonding, hydrophobic contacts and salt bridges. The SARS-COV-2 RdRp interacting residues are shown in blue stick in the lower enlarged panel and labeled by its one-letter code.

Sofosbuvir shows a promaount binding affinity to the RdRp and tightly interacting with the binding site; hence, supposed to be the right candidate against COVID-19. It could be used to inhibit SARS-CoV-2 RdRp, which yet to be confirmed through experimental binding assays. Currently, we are working on modified sofosbuvir compounds to optimize the drug for SARS-CoV-2 RdRp further. Conclusively, in vitro binding studies and in vivo studies needed to confirm our suggestion that Sofosbuvir could be a therapeutic option against SARS-CoV-2 by targeting its polymerase.

Acknowledgement

Computational support from the King Abdullah University of Science and Technology (KAUST HPC allocation grant “K1482”) and COVID-19 Grant by Cairo University, is acknowledged.

Ethics

This article is original and contains unpublished material. The corresponding author confirms that all of the other authors have read and approved the manuscript and no ethical issues involved.

Authors Contributions

Mohamed Nabil: Funding, revisions and final form of the manuscript.

Abdo A Elfiky: Drafting the manuscript and figure Generation.

Reference


